DARE stock: buy or sell?
January 17th, 2020
Daré Bioscience, Inc. develops and commercializes product for women's reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.
Should I buy DARE stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Dare Bioscience stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Dare Bioscience stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we detected 2 ratings published for DARE stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
DARE stock analysis
Dare Bioscience ended yesterday at $1.66 and rose a remarkable 2.47%.
Shares of Dare Bioscience closed yesterday at $1.66 and rose a remarkable 2.47%. Since last Monday when DARE stock price broke up the SMA200d line, it gained $0.82 (97.62%). From a daily perspective, DARE is in a short term uptrend after plotting its last bottom ($0.80, on Jan/7) higher than the previous bottom, and its last top ($2.22, on Monday) also over the previous top. Now trading in between its last bottom and last top DARE might consolidate in a plain range, waiting to break out over $2.22 or down under $0.80. On October, SMA50d and SMA100d crossed up triggering a rise of 97.62%.
Dare Bioscience shares crossed up the SMA line of 200d, closing at $1.66. For 3 weeks in a row, price climbed and marked a profit of 100.00%.
Weekly chart tells us that price finally broke over the resistance at $0.90 and continued climbing.
DARE stock price history
DARE IPO was on April 10th, 2014 at $71.00 per share1. Since then, DARE stock declined a -97.70%, with a yearly average of -19.50%.
1: Adjusted price after possible price splits or reverse-splits.
DARE stock historical price chart
DARE stock reached 52-week highs on March at $3.25, and all-time highs 2015-03-19 with a price of 108.7.
DARE stock price target is $3.00Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price forecast for Dare Bioscience stock was posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter publishing its last earnings report on April, Dare Bioscience . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2014, last anual revenues report draw an exceptional growth of 857.50% to $0.77 million USD. When comparing 2016 vs 2014, similarly, profit margin (that is, the net income divided by revenues) climbed a 24,046.30% to -5,131.20%.
|2013||$6.00 M||-||$0.00 M0.0%||-|
|2014||$0.08 M||-98.67%||$-23.34 M-29177.5%||0.00%|
|2016||$0.77 M||857.50%||$-39.31 M-5131.2%||68.39%|
Quarterly financial resultsReported quarter earnings marked $-2.92 million with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Dare Bioscience sales marked a tight movement and stayed stable a nan%. Looking back to recent quarterly results, Dare Bioscience posted 7 negative quarters in a row.
|2017-Q1||$1,192.00 M||-||$0.00 M0.0%||-|
|2017-Q2||$642.00 M||-46.14%||$0.00 M0.0%||0.00%|
Dare Bioscience ownershipWhen you are planning to invest in shares of a stock, it's worth to have a look its ownership structure.
Dare Bioscience shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 18.95% of all shares.
In case of Dare Bioscience stock, 4.83% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for DARE stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$32.7 M||$540.0 M||$682.6 M||$1.3 B||$4.0 B|
|Total shares||19.7 M||54.8 M||149.7 M||15.4 M||175.9 M|
|Float shares||14.4 M||43.4 M||125.0 M||7.4 M||174.1 M|
|- Institutional holdings (%)||4.8%||106.1%||70.1%||92.2%||102.5%|
|- Insider holdings (%)||18.9%||3.1%||1.4%||10.8%||1.2%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, January 17th, 2020|
|Day range||$1.62 - $1.68|
|Average true range||$0.20|
|50d mov avg||$0.90|
|100d mov avg||$0.85|
|200d mov avg||$0.87|
Dare Bioscience performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We selected Clovis Oncology, ImmunoGen, Madrigal Pharmaceuticals, Nektar, Seattle Genetics and Spectrum Pharmaceuticals as the bechmarking frame for Dare Bioscience stock.